Drugs / DM5167
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07101601 | Oct 2024 → Oct 2026 expected | breast cancer | DIGMBIO | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM5167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07101601 ↗ |
| Action | Inhibit | “DM5167 is a second-generation of PARP inhibitor” NCT07101601 ↗ |
| Target | PARP1 | “selectively targets the PARP-1 enzyme” NCT07101601 ↗ |